Abstract | PURPOSE: METHODS: This study was a prospective, randomized, observer-masked, short-term crossover trial. Eighty-six (86) Asian subjects with newly diagnosed ocular hypertension were randomly assigned to receive either brimonidine 0.2% or brimonidine Purite 0.15%, both dosed twice a day for 4 weeks. Subjects were then washed out for 6 weeks and switched to the opposite treatment for 4 weeks. RESULTS: CONCLUSIONS:
|
Authors | Chan Yun Kim, Samin Hong, Gong Je Seong |
Journal | Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
(J Ocul Pharmacol Ther)
Vol. 23
Issue 5
Pg. 481-6
(Oct 2007)
ISSN: 1080-7683 [Print] United States |
PMID | 17900227
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Adrenergic alpha-Agonists
- Antihypertensive Agents
- Ophthalmic Solutions
- Preservatives, Pharmaceutical
- Quinoxalines
- Brimonidine Tartrate
|
Topics |
- Administration, Topical
- Adrenergic alpha-Agonists
(administration & dosage, adverse effects, therapeutic use)
- Adult
- Antihypertensive Agents
(administration & dosage, adverse effects, therapeutic use)
- Asia
- Asian People
- Brimonidine Tartrate
- Conjunctivitis, Allergic
(chemically induced)
- Cross-Over Studies
- Female
- Humans
- Intraocular Pressure
(drug effects)
- Male
- Ocular Hypertension
(drug therapy)
- Ophthalmic Solutions
- Pigment Epithelium of Eye
(metabolism)
- Preservatives, Pharmaceutical
- Prospective Studies
- Quinoxalines
(administration & dosage, adverse effects, therapeutic use)
- Single-Blind Method
- Therapeutic Equivalency
|